CBLL1 Activators
CBLL1 Activators are a set of chemical compounds specifically identified to bolster the functional activity of CBLL1 through various indirect mechanisms that involve the modulation of cellular signaling pathways. Forskolin, by raising intracellular cAMP levels, indirectly facilitates CBLL1 activity through the activation of PKA, potentially leading to the phosphorylation of proteins that interact with CBLL1, thereby enhancing its functional role. Similarly, EGCG, by inhibiting competitive protein kinases, and LY294002, through PI3K inhibition, alter the cellular signaling dynamics in a way that could indirectly enhance the activity of CBLL1. Sphingosine-1-phosphate operates through its receptors to modulate signaling cascades that control cytoskeletal dynamics, potentially affecting CBLL1 activity. Additionally, compounds such as U0126 and PD 98059 target the MAPK/ERK pathway, where their inhibitory action could redirect signaling through CBLL1-involved pathways, increasing the protein's activity.
Furthermore, A23187, through its ionophoric action, increases intracellular calcium levels, which can activate calcium-dependent kinases that may interact with CBLL1. PMA, a PKC activator, and AM 251, a cannabinoid receptor antagonist, can each modify signaling pathways in a manner that may indirectly lead to enhanced CBLL1 activity. SB 203580's inhibition of p38 MAP kinase and Y-27632's inhibition of ROCK may both result in the activation of alternative signaling routes that involve CBLL1, potentially increasing its activity. Lastly, Genistein serves to reduce tyrosine kinase-mediated competition, which could allow CBLL1 greater substrate access, indirectly increasing its activity. Collectively, these chemical activators, through their targeted effects on various cellular signaling mechanisms, serve to enhance the functional activity of CBLL1 without directly increasing its expression or requiring direct activation of the protein itself.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, leading to increased levels of cyclic AMP (cAMP) in cells. This rise in cAMP can activate protein kinase A (PKA), which may then phosphorylate specific targets that include substrates interacting with CBLL1, thereby enhancing CBLL1 activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a potent antioxidant that inhibits certain protein kinases. By inhibiting these kinases, EGCG may reduce competitive phosphorylation, thus potentially allowing CBLL1 to interact more freely with its substrates and enhance its functional activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
D-erythro-Sphingosine-1-phosphate interacts with its receptors to activate intracellular signaling cascades, including those regulating cytoskeletal rearrangement. This has the potential to enhance CBLL1 activity by modulating interaction partners that are involved in these processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 selectively inhibits MEK, which is upstream of ERK in the MAPK pathway. Inhibition of this pathway can redistribute signaling effort to other pathways, possibly enhancing the functional role of CBLL1 in these alternative pathways. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels. Elevated calcium can activate calcium-dependent protein kinases, which may interact with CBLL1 or its substrates, potentially enhancing the functional activity of CBLL1. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate a wide array of targets. PKC-mediated phosphorylation may indirectly enhance CBLL1 activity if PKC targets interact with or modify the function of CBLL1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a selective inhibitor of p38 MAP kinase. The inhibition of p38 may lead to the activation of alternative signaling pathways, some of which could involve CBLL1, potentially enhancing the functional activity of CBLL1. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of the Rho-associated protein kinase (ROCK). Inhibition of ROCK can lead to changes in actin cytoskeleton dynamics and cell motility, potentially affecting CBLL1 activity by altering the cellular context in which it operates. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is an isoflavone that acts as a tyrosine kinase inhibitor. By inhibiting these kinases, genistein may enhance CBLL1 activity by reducing phosphorylation-based competition, thus potentially allowing CBLL1 greater access to its substrate proteins. | ||||||